MoonLake Immunotherapeutics (MLTX)
- Sector
- Biotechnology
- Last price
- $12.31
- As of
Kresmion compiles this page from MLTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MoonLake Immunotherapeutics (MLTX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-30.
See the full MLTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MLTX on one page. Preview it with sample data, then open it live with a free account.
Preview the MLTX dossierActive events for MLTX
- high13F: funds added
3 tracked funds increased MLTX this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 10.4%, EPS $-0.84 vs $-0.937 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +368% to MLTX (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +132% to MLTX (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +53% to MLTX (2026Q2)
FREE, NO ACCOUNT
Every event on MLTX, as it fires
You are seeing 5 of 11 events recorded on MLTX since 2026-05-26.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MLTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 61559X104 · 2026Q2 | $65.5M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 61559X104 · 2026Q2 | $38.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 61559X104 · 2026Q2 | $33.4M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 61559X104 · 2026Q2 | $22.6M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 61559X104 · 2026Q2 | $12.5M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 61559X104 · 2026Q2 | $12.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MLTX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
MLTX against its peers
MLTX's return on equity of -74.7% ranks in the 22nd percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | MLTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 81.4M | n/a | 9 |
| Operating margin | n/a | -130.2% | n/a | 9 |
| Net margin | n/a | -140.3% | n/a | 9 |
| Return on equity | -74.7% | -38.3% | 22 | 15 |
Peers (18): SVRA, AVBP, SGP, ORIC, MNKD, JBIO, GLUE, VSTM, CGEM, INBX, RAPP, RIGL, MGTX, TBPH, CRVS, JANX, IMTX, KURA. Left out: LTGO (no annual filing), CTY (no annual filing), SPTX (no annual filing), IVA (period gap), AKTS (no annual filing), OBX (no annual filing), SLBT (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (MLTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MLTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MLTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.